Tactical Therapeutics is a clinical stage company that has developed and patented a First-in-class therapeutic Carboxyamidotriazole Orotate (CTO) for Orphan indication glioblastoma (GBM) and resistant solid cancers. CTO is an oral drug which has shown Safety and Efficacy in very sick GBM and Solid Cancer patients in three Phase 1 trials.
CTO has shown compelling results where historically no treatment has helped. CTO overcomes significant obstacles including delivery through the blood brain barrier (BBB), targets multiple cell types, blocks out multiple genomic pathways and processes of cancer proliferation, invasion, and immunosuppression, thus preventing the number one problem in cancer today, resistance. Phase 2/3 trial on the Accelerated Approval path are planned in recurrent and newly diagnosed GBM patients. Company is pursuing partnering strategies to raise the funding to run these trials.